Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework

Article Critical Care Medicine

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies-Gow et al.

Summary: This study evaluated the impact of reducing oral corticosteroids after initiating benralizumab treatment on patients with severe eosinophilic asthma. The study found that with a personalized dosage reduction algorithm, most patients were able to successfully reduce or eliminate the use of oral corticosteroids, and the treatment was safe.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Respiratory System

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Simon Couillard et al.

Summary: A risk scale predicting asthma attacks based on blood eosinophil count and exhaled nitric oxide (FeNO) was proposed, showing potential to predict and prevent asthma attacks through anti-inflammatory treatment.

THORAX (2022)

添加到收藏夹

Article Critical Care Medicine

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

Michael E. Wechsler et al.

Summary: This study evaluated the efficacy of tezepelumab in reducing oral corticosteroid dose in patients with oral corticosteroid-dependent asthma. The results showed no significant improvement in the overall population, but improvement was observed in patients with higher baseline blood eosinophil counts.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Letter Respiratory System

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)

Simon Couillard et al.

ERJ OPEN RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

Andrew Menzies-Gow et al.

Summary: Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, effectively reduces asthma exacerbations in patients with severe, uncontrolled asthma, leading to improved lung function, asthma control, and quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Critical Care Medicine

Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma

Simon Couillard et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Workup of Severe Asthma

Simon Couillard et al.

Summary: This article reviews the clinical assessment of a 56-year-old man with difficult-to-control asthma and a history of exacerbations, highlighting the importance of identifying different asthma phenotypes and using biomarkers to guide treatment decisions. The patient was found to have severe asthma with ICS-resistant type 2 airway inflammation, and additional treatment options will be considered in the future.

CHEST (2021)

添加到收藏夹

Article Respiratory System

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

Monica Kraft et al.

Summary: This study identified clinical characteristics and biomarkers associated with elevated exacerbation risk in severe, uncontrolled asthma patients. Factors such as exacerbation history, maintenance corticosteroid use, nasal polyposis, Asian race, geographic region, and elevated blood eosinophil counts and F-ENO concentrations were found to be correlated with increased exacerbation risk when combined or persistently achieving type 2 inflammation criteria.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Letter Critical Care Medicine